EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Flawless balance sheet with proven track record.
Share Price & News
How has EKF Diagnostics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EKF's share price has been volatile over the past 3 months.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: EKF underperformed the UK Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: EKF exceeded the UK Market which returned -22.7% over the past year.
Price Volatility Vs. Market
How volatile is EKF Diagnostics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDoes This Valuation Of EKF Diagnostics Holdings plc (LON:EKF) Imply Investors Are Overpaying?
3 weeks ago | Simply Wall StWhy EKF Diagnostics Holdings plc's (LON:EKF) CEO Pay Matters To You
1 month ago | Simply Wall StDo You Like EKF Diagnostics Holdings plc (LON:EKF) At This P/E Ratio?
Is EKF Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EKF (£0.28) is trading above our estimate of fair value (£0.18)
Significantly Below Fair Value: EKF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EKF is good value based on its PE Ratio (11.8x) compared to the Medical Equipment industry average (26.9x).
PE vs Market: EKF is good value based on its PE Ratio (11.8x) compared to the UK market (12.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EKF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EKF is good value based on its PB Ratio (1.9x) compared to the GB Medical Equipment industry average (2.9x).
How is EKF Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EKF's forecast earnings growth is above the savings rate (0.5%).
Earnings vs Market: Insufficient data to determine if EKF's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EKF's revenue (4.7% per year) is forecast to grow faster than the UK market (2.6% per year).
High Growth Revenue: EKF's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EKF's Return on Equity is forecast to be high in 3 years time
How has EKF Diagnostics Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKF has a large one-off gain of £6.7M impacting its June 30 2019 financial results.
Growing Profit Margin: EKF's current net profit margins (24.7%) are higher than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: EKF has become profitable over the past 5 years, growing earnings by 51.7% per year.
Accelerating Growth: EKF's earnings growth over the past year (195%) exceeds its 5-year average (51.7% per year).
Earnings vs Industry: EKF earnings growth over the past year (195%) exceeded the Medical Equipment industry -7.4%.
Return on Equity
High ROE: EKF's Return on Equity (16.4%) is considered low.
How is EKF Diagnostics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: EKF's short term assets (£27.7M) exceed its short term liabilities (£15.3M).
Long Term Liabilities: EKF's short term assets (£27.7M) exceed its long term liabilities (£4.3M).
Debt to Equity History and Analysis
Debt Level: EKF's debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: EKF's debt to equity ratio has reduced from 6% to 1.5% over the past 5 years.
Inventory Level: EKF has a high level of physical assets or inventory.
Debt Coverage by Assets: EKF's debt is covered by short term assets (assets are 28.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EKF is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: Insufficient data to determine if EKF has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is EKF Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EKF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EKF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EKF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EKF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EKF's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Julian Baines (54yo)
Mr. Julian Huw Baines, MBE, is Non-Executive Chairman of Renalytix AI plc. Mr. Baines serves as the Chief Executive Officer and Executive Director of EKF Diagnostics Holdings plc. Mr. Baines serves as a Di ...
CEO Compensation Analysis
Compensation vs Market: Julian's total compensation ($USD429.47K) is below average for companies of similar size in the UK market ($USD761.42K).
Compensation vs Earnings: Julian's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||no data||UK£346.00k||0.41% £519.5k|
|COO, Finance Director & Executive Director||no data||UK£283.00k||0.039% £50.1k|
|Non-Executive Chairman||3.92yrs||UK£25.00k||0.033% £42.0k|
|Non-Executive Director||3.67yrs||UK£25.00k||no data|
|Senior Independent Director||no data||UK£30.00k||0.37% £467.2k|
Experienced Board: EKF's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EKF Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources
- Name: EKF Diagnostics Holdings plc
- Ticker: EKF
- Exchange: AIM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£127.146m
- Shares outstanding: 454.09m
- Website: https://www.ekfdiagnostics.com
Number of Employees
- EKF Diagnostics Holdings plc
- Avon House
- 19 Stanwell Road
- South Glamorgan
- CF64 2EZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EKF||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Jun 2002|
|EKDH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2002|
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally. It offers DiaSpect Tm and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers’ milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; reagents, calibrators, standards, and controls; immunoassay kits; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; sTNFRr1, a predictive marker of end stage renal disease; and Uri-Trak 120 urine analyzer. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 20:58|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.